The vaccine against human papilloma virus (HPV) infection was included in the vaccination calendar in 2007. An infection with uterine cancer, causing HPV is transmitted through sexual intercourse.

In the course of life, about 70% of sexually active women become infected with HPV. In the majority of infected young women (70-90%), the body’s immune system copes with the infection itself. In the remaining cases, the virus can persist and cause cervical cancer years or decades later. Every year, around 6,500 women in Germany contract cervical cancer.

Vaccination: dead vaccine, injection into the muscle. The vaccine contains particles that resemble the surface proteins of the HPV virus (virus-like particles). These particles themselves have no disease-causing properties.

Who should vaccinate?

  • All girls from 12 to 17 years old.
  • Women who have not been vaccinated against HPV within this period can also benefit from HPV vaccine later. It is the responsibility of the attending physician to inform his patients about the benefits and risks of the vaccination on the basis of the vaccine approval.

Time of vaccination: The vaccination with 3 doses should be completed before the first sexual intercourse.

Frequent vaccination reactions: fever, pain, redness and swelling at the injection site. Itching and bleeding at the injection site.

What else needs to be considered? The HPV vaccination cannot replace the offer of gynecological check-ups. These are still at the same distance as previously required.